With global obesity bursting at the seams, keep an eye on stocks like Altimmune (ALT).
Recent Phase 2 results showed that patients lost an average of 15.6% of their body weight at 48 weeks at the highest dose. The study also found that the treatment led to better lean mass preservation as compared to other similar weight loss treatments.
“Preservation of lean mass, which is primarily muscle tissue, is believed to be important in maintaining healthy weight loss and physical function,” CEO Vipin Garg said in a news release. “We believe that the level of muscle preservation observed in the Phase 2 trial further adds to the differentiation of pemvidutide in the treatment of obesity.”
As for its potential reach, according to the World Health Organization, obesity has more than doubled since 1990. In fact, global adult obesity has more than doubled since 1990, and adolescent obesity has quadrupled. And over 390 million children and adolescents aged five to 19 years were overweight in 2022, including 160 million who were living with obesity.